share_log

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.5

Benzinga Real-time News ·  Aug 15, 2022 09:08

HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $2 to $1.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment